46863, a novel human methyltransferase and uses thereof
OwnerRachel Meyers, Mark Williamson +1inventors
InventorsRachel Meyers, Mark Williamson, Laura A. Rudolph-Owen
Life of this patent
Estimating the term…
Abstract
The invention provides isolated nucleic acid molecules, designated TPRM nucleic acid molecules, which encode novel methyltransferase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing TPRM nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a TPRM gene has been introduced or disrupted. The invention still further provides isolated TPRM proteins, fusion proteins, antigenic peptides and anti-TPRM antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.
Claims30
An isolated nucleic acid molecule selected from the group consisting of:
- (a) a nucleic acid molecule comprising the nucleotide sequence set forth in SEQ ID NO:1;
- and
- (b) a nucleic acid molecule comprising the nucleotide sequence set forth in SEQ ID NO:3.
An isolated nucleic acid molecule which encodes a polypeptide comprising the amino acid sequence set forth in SEQ ID NO:2.
An isolated nucleic acid molecule which encodes a naturally-occurring allelic variant of a polypeptide comprising the amino acid sequence set forth in SEQ ID NO:2.
An isolated nucleic acid molecule selected from the group consisting of:
- (a) a nucleic acid molecule comprising a nucleotide sequence which is at least 60% identical to the nucleotide sequence of SEQ ID NO:1 or 3, or a complement thereof;
- (b) a nucleic acid molecule comprising a fragment of at least 30 nucleotides of a nucleic acid comprising the nucleotide sequence of SEQ ID NO:1 or 3, or a complement thereof;
- (c) a nucleic acid molecule which encodes a polypeptide comprising an amino acid sequence at least about 60% identical to the amino acid sequence of SEQ ID NO:2;
- and
- (d) a nucleic acid molecule which encodes a fragment of a polypeptide comprising the amino acid sequence of SEQ ID NO:2, wherein the fragment comprises at least 10 contiguous amino acid residues of the amino acid sequence of SEQ ID NO:2.
An isolated polypeptide selected from the group consisting of:
- a) a fragment of a polypeptide comprising the amino acid sequence of SEQ ID NO:2, wherein the fragment comprises at least 10 contiguous amino acids of SEQ ID NO:2;
- b) a naturally occurring allelic variant of a polypeptide comprising the amino acid sequence of SEQ ID NO:2, wherein the polypeptide is encoded by a nucleic acid molecule which hybridizes to complement of a nucleic acid molecule consisting of SEQ ID NO:1 or 3 under stringent conditions;
- c) a polypeptide which is encoded by a nucleic acid molecule comprising a nucleotide sequence which is at least 60% identical to a nucleic acid comprising the nucleotide sequence of SEQ ID NO:1 or 3;
- and
- d) a polypeptide comprising an amino acid sequence which is at least 60% identical to the amino acid sequence of SEQ ID NO:2.
A method of identifying a subject having a cellular proliferation, growth, apoptosis, differentiation, and/or migration disorder, or at risk for developing a cellular proliferation, growth, apoptosis, differentiation, and/or migration disorder comprising:
- a) contacting a sample obtained from said subject comprising nucleic acid molecules with a hybridization probe comprising at least 25 contiguous nucleotides of SEQ ID NO:1;
- and
- b) detecting the presence of a nucleic acid molecule in said sample that hybridizes to said probe, thereby identifying a subject having a cellular proliferation, growth, apoptosis, differentiation, and/or migration disorder.
A method of identifying a subject having a cellular proliferation, growth, apoptosis, differentiation, and/or migration disorder, or at risk for developing a cellular proliferation, growth, apoptosis, differentiation, and/or migration disorder comprising:
- a) contacting a sample obtained from said subject comprising nucleic acid molecules with a first and a second amplification primer, said first primer comprising at least 25 contiguous nucleotides of SEQ ID NO:1 and said second primer comprising at least 25 contiguous nucleotides from the complement of SEQ ID NO:1;
- b) incubating said sample under conditions that allow nucleic acid amplification;
- and
- c) detecting the presence of a nucleic acid molecule in said sample that is amplified, thereby identifying a subject having a cellular proliferation, growth, apoptosis, differentiation, and/or migration disorder, or at risk for developing a cellular proliferation, growth, apoptosis, differentiation, and/or migration disorder.
A method of identifying a subject having a cellular proliferation, growth, apoptosis, differentiation, and/or migration disorder, or at risk for developing a cellular proliferation, growth, apoptosis, differentiation, and/or migration disorder comprising:
- a) contacting a sample obtained from said subject comprising polypeptides with a TPRM binding substance;
- and
- b) detecting the presence of a polypeptide in said sample that binds to said TPRM binding substance, thereby identifying a subject having a cellular proliferation, growth, apoptosis, differentiation, and/or migration disorder, or at risk for developing a cellular proliferation, growth, apoptosis, differentiation, and/or migration disorder.
A method for identifying a compound capable of treating a cellular proliferation, growth, apoptosis, differentiation, and/or migration disorder characterized by aberrant TPRM nucleic acid expression or TPRM polypeptide activity comprising assaying the ability of the compound to modulate TPRM nucleic acid expression or TPRM polypeptide activity, thereby identifying a compound capable of treating a cellular proliferation, growth, apoptosis, differentiation, and/or migration disorder characterized by aberrant TPRM nucleic acid expression or TPRM polypeptide activity.
A method for treating a subject having a cellular proliferation, growth, apoptosis, differentiation, and/or migration disorder characterized by aberrant TPRM polypeptide activity or aberrant TPRM nucleic acid expression comprising administering to the subject an TPRM modulator, thereby treating said subject having a cellular proliferation, growth, apoptosis, differentiation, and/or migration disorder.
Dependencies are inferred from the claim text.